




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁶ : A61K 39/116, 9/02</p>	<p>A1</p>	<p>(11) International Publication Number: WO 99/11286</p> <p>(43) International Publication Date: 11 March 1999 (11.03.99)</p>
<p>(21) International Application Number: PCT/US98/18402</p> <p>(22) International Filing Date: 3 September 1998 (03.09.98)</p> <p>(30) Priority Data: 08/923,813 4 September 1997 (04.09.97) US</p> <p>(71) Applicant: PROTEIN EXPRESS [US/US]; Hoxworth Center, 3rd floor, 3130 Highland Avenue, Cincinnati, OH 45219 (US).</p> <p>(72) Inventors: HERTELENDY, Zsolt, Istvan; 3270 Linwood Avenue, Cincinnati, OH 45226-1292 (US). WEINER, Murray; 8915 Spooky Ridge Lane, Cincinnati, OH 45242 (US).</p> <p>(74) Agent: MIZER, Susan, L.; Benesch, Friedlander, Coplan & Aronoff LLP, 2300 BP America Building, 200 Public Square, Cleveland, OH 44114-2378 (US).</p>	<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>	

(54) Title: VAGINAL SUPPOSITORY VACCINE FOR UROGENITAL INFECTIONS



(57) Abstract

This invention is directed to a suppository-based vaccine delivery system for immunizing against urogenital infectious disease in humans and a method for treating same. More particularly, this invention is directed to a suppository-based vaccine delivery system for the prophylaxis against urogenital infectious diseases, such as urinary tract infections. The suppository-based vaccine delivery system is comprised of a vaccine comprised of inactivated bacteria which originate from cultures of 8 to 14 uropathogenic bacteria strains of species: *Escherichia coli*, *Klebsiella pneumoniae*, *Proteus mirabilis*, *Proteus morganii*, and *Streptococcus faecalis*; and polyethylene glycol suppository base; wherein the suppository is adapted to be inserted into a bodily orifice of a human so as to allow the suppository to be in contact with tissue of the bodily orifice to facilitate transfer of suppository material therethrough.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

VAGINAL SUPPOSITORY VACCINE FOR UROGENITAL INFECTIONS

Field of Invention

The present invention relates generally to a system and method for treating disease in humans, specifically a prophylactic treatment of urogenital infections in humans. More particularly, the invention relates to a suppository-based, intravaginal vaccine delivery system for prophylaxis against urinary tract infections in humans, wherein the suppository is comprised of a vaccine derived from whole or fractionated pathogenic microorganisms. Still more particularly, the present invention relates to a suppository based delivery system for prophylaxis against recurrent urinary tract infections in humans, wherein the suppository is comprised of a vaccine of whole, inactivated bacteria which originate from cultures of 4 to 20 uropathogenic bacterial strains isolated from the urine of persons suffering urinary tract infections, and which include a polyethylene glycol suppository base.

Background of the Invention

Urinary tract infections are a major problem in medicine. Every part of the urinary tract may be affected. The most common forms of the illness are: cystitis, the urethral syndrome, pyelitis, and pyelonephritis. A tendency for recurrence and chronic progression is characteristic of urinary tract infections. The disease is ten times more common in women than men. This difference is due mainly to the fact that the particular anatomy of the female urethra favors infection by the body's own bacterial intestinal flora. The main diagnostic criterion of urinary tract infections is bacteriuria, the presence

of bacteria in the properly collected urine sample (midstream urine). For bacteriuria to be considered diagnostically significant, it has to exceed a concentration of 10^5 bacteria per milliliter of urine.

5 Bacteria that reach the urinary tract establish infection either through the bloodstream or by ascending from the urethra to the bladder and then up the ureter to the kidneys. Ascending infection is the most common mode and explains the more frequent occurrence in women. The position of the urethral ostium and the short urethra in women favor infection. Various bacteria originating from the fecal flora are always resident in the urethral ostium and in the distal part of the female urethra. Urinary tract infections
10 in women is initiated when one of the *Enterobacteriaceae* derived from the fecal flora colonizes in the vaginal vestibule.

The most frequent and abundant constituent of the fecal flora is *Escherichia coli*, which is also frequently found in the urine as the causative organism in urinary tract infections. *Escherichia coli* is also usually found in the periurethral region. This bacterium is capable of adhering to the periurethral epithelial cells.
15 Bacterial adherence is the precondition for the colonization and infection of the urinary tract. Many in-vitro studies have shown that the adherence phenomenon is due to the possession of pili by *Escherichia coli* that infect the urinary tract. *Escherichia coli* bacteria are the most frequent causative agents of urinary tract infections.

20 The urinary tract can also be colonized by other *Enterobacteria*, such as *Proteus* and *Klebsiella*, and gram positive cocci such as *Staphylococcus* and *Streptococcus faecalis* (*Enterococcus*). Other bacteria such as *Pseudomonas aeruginosa*

and *Haemophilus influenzae* may also invade the urinary tract. Any of the bacterial inhabitants of the intestinal tract that are eliminated in the feces may populate the urinary tracts. Further, the human urinary tract can be colonized by mycoplasma, L-forms of bacteria, Chlamydia, fungi, viruses, and protozoa.

5 Recurrence and chronicity are characteristic of urinary tract infections. Recurrence may be due to either relapse or reinfection. In spite of a great deal of progress in the treatment of other bacterial infections, the morbidity and mortality of urinary tract infections's remains unchanged in the last 20 to 25 years. The reasons for this are myriad and depend on the host organism and on microbial factors.

10 Recurrences of infections with a previously infecting organism strain are rare and may result from incorrect choice of medicine, emergence of resistance strains, insufficient treatment duration, insufficient concentration of antibacterial agents, the existence of bacterial L-forms, and survival of organisms in urinary calculi. Recurrent urinary tract infections in women are essentially all reinfections with different organisms
15 and generally with strains having a greater capacity to adhere to the epithelial cells of the vagina and urethra. The re-infecting bacteria originate in the intestinal flora. The composition of the intestinal flora may be altered by prophylactic and therapeutic use of antibiotics and other antibacterial materials which are used in the treatment and prophylaxis of urinary tract infections. The intestinal flora frequently develop antibiotic
20 resistance and the resistant bacteria may then cause a reinfection or primary opportunistic infection of the urinary tract. Such primary infections may be due to opportunistic germs that result from the normal, harmless flora, such as lactobaelli, being wiped out by

antibiotics. Other microbes, resistant to the antibiotics, can now flourish and become pathogenic. The bacterial antibiotic resistance caused by R-plasmids is not only transferred between the same species of bacteria, but is also transmitted to almost all *Enterobacteriaceae*. Multiresistance is also common.

5 The main cause of recurrent urinary tract infections in women is an immunological defect which facilitates the adhesion of uropathogenic organisms to the periurethral region. Studies have revealed that low levels of urine secretory IgA (sIgA) in urine indicate a defective local immune response of the urinary tract and favor recurrent ascending urinary tract infections. The most important property of sIgA is that they prevent the interaction of bacterial pili with the specific receptors found on the epithelia of the urinary tract. Pili-mediated adhesiveness is an important virulence factor of the bacterial involved. For the defense against infection it is important to reduce the adhesion of the pathogens to the urothelium or to prevent the attachment of the bacteria altogether.

15 Normally, the host organism forms specific local antibodies against the invading bacteria and secretes these antibodies as sIgA. In patients with persisting or frequently relapsing urinary tract infections this natural mechanism of local immunological infection defense is apparently disturbed. Therefore, enhancement of immune defense is a rational means of eliminating the cause of recurrent urinary tract infections. A vaccination which stimulates the production of antibodies to a spectrum of antigens that are present in several types of *Escherichia coli* and other commonly occurring urinary bacteria is particularly appropriate.

Previously, urinary tract infections vaccines have been administered parenterally or orally and have resulted in enhanced resistance to urinary tract infections. Parenteral administration of SOLCOUROVAC®, a urinary tract infections vaccine manufactured by Solco Basel AG, Basel Switzerland and described in U.S. Patent No. 4,606,919, the contents of which are incorporated herein in entirety, decreased post-hysterectomy urinary tract infections, reduced the frequency of infections in susceptible women, and increased sIgA. However, some patients suffered from side effects such as malaise, fever, and muscle soreness. An oral vaccine consisting of immunostimulatory fractions extracted from *Escherichia coli* strains decreased bacteriuria, septic episodes, requirements for antibiotics in spinal cord injury patients, and the incidence of recurrent urinary tract infections in adult women. As with the parenteral administration, many patients suffered from adverse reactions.

In an attempt to overcome the defects associated with parenteral and oral administrations of urinary tract infections vaccine, an intravaginal vaccine against urinary tract infections was proposed. The rationale for administering a urinary tract infections vaccine intravaginally was that there is a mucosal immune system wherein antigens are absorbed through mucosal surfaces and processed by specialized local lymphoid tissues, after which antibodies are secreted onto local mucosal surfaces. As discussed above, in the genitourinary tract, temporary or partial deficiencies in local vaginal or urinary antibodies are an important factor in the heightened susceptibility to urinary tract infections shown in some women. Immunization via the mucosal surfaces within the genitourinary tract are preferable to parental or oral routes as it has been discovered that

vaccination via the intravaginal surface creates a secretory immune response in the urogenital tract.

In the past, urinary tract infections vaccines were administered vaginally in the form of a liquid vaccine. Several problems were associated with the intravaginal administration of liquid urinary tract infections vaccine. The major problem encountered
5 was that the liquid vaccine flowed out of the vagina soon after insertion. This severely limits the amount of time that the liquid antigens are in contact with the mucosal surface of the vagina, decreasing the effectiveness of the vaccine. The antigens need sufficient contact with the vaginal mucous membrane to elicit a secretory immunoglobulin response.

10 Patients receiving the vaccination were required to lie in a supine position for an extended time after receiving the vaccine to prevent the vaccine from immediately flowing out of the vagina. However, often the vaccine still leaked out of the vagina following the period of time in the supine position, limiting the effectiveness of the vaccine.

15 In addition, the requirement that patients lie in a supine position for an extended time after receiving the vaccine, is a burden on the patient. Patients may receive several vaccinations over the course of treatment and the patients must spend a considerable amount of time after each vaccination immobile. Therefore, it is apparent that improvements are necessary in the prophylaxis against urogenital infectious diseases,
20 such as urinary tract infections, and urinary tract infection vaccines.

The subject invention overcomes the above limitations and others, and teaches a suppository-based vaccine delivery system for prophylaxis against urogenital infectious diseases, such as urinary tract infections.

5

Summary of the Invention

According to the present invention, there is provided a intravaginally administered suppository-based vaccine delivery system for prophylaxis against urogenital infectious diseases, such as urinary tract infections.

10

Further according to the present invention, there is provided a suppository-based vaccine delivery system for the prophylaxis against urogenital infectious diseases, such as urinary tract infections wherein the vaccine is in contact with the vaginal mucous membrane for a sufficient period of time to enhance the immune response.

15

Still further according to the present invention, there is provided a suppository-based vaccine delivery system for the prophylaxis against urogenital infectious diseases, such as urinary tract infections, wherein the vaccine is easily administered, does not require the patient to lie in a supine position for an extended period of time after receiving the vaccination, and is suitably administered by the patient for primary and routine booster requirements.

20

Still further according to the present invention, there is provided a suppository-based vaccine delivery system for prophylaxis against urogenital infectious diseases, such as urinary tract infections in humans, said suppository comprising: a vaccine comprised of inactivated bacteria which originate from cultures of 8 to 14

uropathogenic bacteria strains isolated from the urine of persons suffering from a urinary tract infection of the species: *Escherichia coli*, *Klebsiella pneumoniae*, *Proteus mirabilis*, *Proteus morgani*, and *Streptococcus faecalis*, and are present in an amount of about 50 million to about 5 billion germs of each strain per suppository, wherein one-half to three-quarters of the strains used belong to *Escherichia coli* species; and polyethylene glycol suppository base; wherein the suppository is adapted to be inserted vaginally so as to allow the suppository to be in contact with vaginal mucous membrane to facilitate transfer of suppository material therethrough.

An advantage of the present invention is the provision of a suppository-based vaccine delivery system for the prophylaxis against urogenital infectious diseases, such as urinary tract infections, wherein the vaccine is in contact with the vaginal mucous membrane for a sufficient period of time to enhance the immune response.

Another advantage of the present invention is the provision of a suppository-based vaccine delivery system for the prophylaxis against urogenital infectious diseases, such as urinary tract infections, wherein the vaccine is easily administered, and does not require the patient to be in a supine position for an extended period of time after receiving the vaccination.

Another advantage of the present invention is the provision of a suppository-based vaccine delivery system wherein the vaccine is suitably administered by the patient.

Another advantage of the present invention is the provision of a suppository-based vaccine delivery system wherein the administration of the vaccine is relatively painless.

5 Yet another advantage of the present invention is the provision of a suppository-based vaccine delivery system wherein sIgA - specific stimulation from mucosal vaccination allows immune responses to specifically keep bacterial colonization from occurring, instead of fighting the infection once it has colonized.

10 Yet another advantage of the present invention is the provision of a suppository-based vaccine delivery system wherein the patient may self-administer booster vaccinations periodically.

Still other advantages of the invention will become apparent to those skilled in the art upon a reading and understanding of the following detailed description, accompanying drawings and appended claims.

15 **Brief Description of the Drawings**

The invention may take physical form in certain parts and arrangements of parts, a preferred embodiment and method of which will be described in detail in this specification and illustrated in the accompanying drawings which form a part hereof, and wherein:

20 Fig. 1 is a graph illustrating the percentage of patients remaining infection free during the course of the testing.

Detailed Description of the Preferred Embodiment

This invention is directed to a suppository-based vaccine delivery system for immunizing against infectious disease in humans and a method for treating same. More particularly, this invention is directed to a suppository-based vaccine delivery system for the prophylaxis against urogenital infectious diseases, such as urinary tract infections. The suppository-based vaccine delivery system is comprised of a vaccine comprised of inactivated bacteria which originate from cultures of 8 to 14 uropathogenic bacteria strains of the species: *Escherichia coli*, *Klebsiella pneumoniae*, *Proteus mirabilis*, *Proteus morganii*, and *Streptococcus faecalis*; and polyethylene glycol suppository base; wherein the suppository is adapted to be inserted into a bodily orifice of a human so as to allow the suppository to be in contact with tissue of the bodily orifice to facilitate transfer of suppository material therethrough.

The suppository is comprised of a vaccine comprised of inactivated bacteria which originate from cultures of 8 to 14 uropathogenic bacteria strains of the species: *Escherichia coli*, *Klebsiella pneumoniae*, *Proteus mirabilis*, *Proteus morganii*, and *Streptococcus faecalis*. The inactivated bacteria are present in an amount of about 50 million to about 5 billion germs of each strain per suppository and one half to three-quarters of the strains used belong to the *Escherichia coli* species. Preferably, the inactive bacteria originate from 6 strains of the species *Escherichia coli* and 1 strain each of *Klebsiella pneumoniae*, *Proteus mirabilis*, *Proteus morganii*, and *Streptococcus faecalis*. In a preferred embodiment, the inactive bacteria are present in the total amount of about 1×10^9 to about 1×10^{10} germs.

The suppository is comprised of a vaccine which is prepared according to the method described in U.S. Patent No. 4,606,919, which is incorporated by reference in its entirety. The vaccine is prepared by culturing, by themselves on a suitable nutrient medium, each of the abovementioned 8 to 14 uropathogenic bacteria strains which have
5 been isolated from the urine of persons suffering from an infection of the urinary tract and, when culturing is concluded, removing the particular biological material formed and inactivating it by known methods, mixing amounts of the inactivated bacteria obtained from the individual strains with one another and diluting the mixture with an amount of a sterile isotonic solution such that about 50 million to 5 billion germs of each strain are
10 present per suppository.

Urine samples (mid-stream urine) were first isolated from persons suffering from a urinary tract infection and inoculated immediately onto a MacConkey agar; after the inoculation, the agar plates were incubated at 37° C for 16 to 18 hours and the colonies formed were then isolated and identified by determination of their
15 biochemical and biological properties.

The colonies identified in this manner were allowed to grow further on agar plates at 37° C for 24 hours and were then suspended in physiological saline solution, tested for purity by means of Gram staining and freeze-dried.

To prepare the vaccines, the strains were cultured individually on a solid
20 or liquid nutrient medium; a solid nutrient medium is preferably used, for example nutrient agar such as Nutrient Agar Difco. The medium is sterilized at 121° C for 15 minutes and it has a pH of about 7.2.

Roux bottles are used for large-scale preparation, and Petri dishes are used for preparation in the laboratory. Inoculation is carried out with inoculum material, a few milliliters of which are uniformly distributed over the entire surface. The Roux bottles are closed with cottonwool plugs and the medium is stored with the inoculated surface at the bottom. The inoculated cultures are incubated at 37°C for 24 hours.

The bacterial lawns are rinsed off with the required amount (depending on the density of growth of the culture in the vessel) of phosphate buffer/saline solution with gentle swirling, without damaging the agar surface.

A smear is obtained from each bottle or each Petri dish, stained by the Gram method and tested for purity. Bottles or Petri dishes which appear to be contaminated are discarded. Suspensions which originate from one strain and one harvest are poured together through a sterile nylon gauze.

Inactivation, like the culture itself, takes place individually for each strain. It can be carried out by heating at a temperature of about 55°C to about 60°C for about one hour, by treatment with formaldehyde solution or by irradiation with γ -rays. Because of its simplicity, inactivation by heating is preferred. The amounts obtained by culture are combined and inactivated in a waterbath at 60°C for one hour, and phenol is added after the inactivation.

The contents of the stock container (inactivated suspensions originating from one strain) are centrifuged at 3,000 rpm for 1 hour in a cooled centrifuge, the supernatant liquid is removed and the bacterial sediment is suspended in saline solution containing 0.01% of thimerosal. The suppository of the present invention is

comprised of any suitable polyethylene glycol suppository base known in the art. More particularly, the polyethylene glycol suppository base is comprised of polyethylene glycol and polysorbate. Preferably, the polyethylene glycol suppository base is comprised of about 98% by weight polyethylene glycol and about 2% by weight polysorbate. Preferably, the polyethylene glycol has an average molecular weight of about 3000 to 5000. In a more preferred embodiment, the polyethylene glycol suppository base is comprised of about 39% by weight of polyethylene glycol having a molecular weight of 8000 and 59% by weight of polyethylene glycol having a molecular weight of 400. A suitable commercially available polyethylene glycol suppository base is POLYBASE, manufactured by Paddock Laboratories, Inc.

The polyethylene glycol suppository base is present in the suppository-based vaccine delivery system in any suitable amount so as to allow the vaccine to be in contact with the vaginal mucous membrane for a sufficient period of time to enhance the immune response. Preferably, the polyethylene glycol suppository base comprises from about 80% to 95% by weight of the suppository. The polyethylene glycol suppository base confers a degree of miscibility with the mucous membrane surfaces of the vagina, wherein suspended particles of the vaccine are in contact with such mucous membrane surfaces for a sufficient amount of time to elicit a secretory immunoglobulin response. The polyethylene glycol suppository base has an adjuvant effect which enhances the immune response by allowing the vaccine to facilitate contact time with the vaginal mucous membranes, serving as a depot that slowly releases antigen, and by localizing and

delivering antigens to immunocompetent cells. The polyethylene glycol suppository base further functions as a structural necessity which keeps the suppository in its molded form.

The suppository is inserted into a laminate suppository shell which forms a molded shape. The suppository is stored in the shell until used. The laminate suppository shell is any shell known in the art suitable for packaging of the suppository. The suppository shell must be able to withstand temperatures of 60°C used in manufacturing the suppositories and temperatures of 4°C for long-term storage without compromising the integrity of the mold or reacting with the suppository in an unfavorable manner. Preferably, the laminate suppository shell is a polyvinyl chloride-polyethylene laminate suppository shell. A suitable commercially available laminate suppository shell is a polyvinyl chloride-polyethylene laminate suppository shell manufactured by Paddock Laboratories, Inc.

The suppository-based vaccine system suitably further comprises depolarized gelatin. The depolarized gelatin is any suitable depolarized gelatin known in the art. Example of suitable depolarized gelatin materials include, but are not limited to, Type A or B gelatin from bovine or porcine collagen. Preferably, the depolarized gelatin is Type A gelatin. The depolarized gelatin serves to protect components during lyophilization.

The depolarized gelatin is present in the suppository in any suitable amount. More particularly, the suppository is comprised of from about 0.01% to about 0.02% by weight depolarized gelatin.

The suppository-based vaccine system suitably further comprises thimerosal. The thimerosal is antimicrobial preservative. A suitable commercially available thimerosal is available from Sigma Chemical Co. The thimerosal is present in the suppository in any suitable amount. More particularly, the suppository is comprised
5 of from about 0.0005% to about 0.005% by weight thimerosal.

The suppository-based vaccine delivery system of the present invention is prepared under an aseptically sterile laminar flowhood. The polyethylene glycol suppository base is heated to a temperature of about 80°C such that the polyethylene glycol becomes liquefied. The polyethylene glycol suppository base is heated for about
10 1 hour. The vaccine comprised of 8 to 14 strains of inactivated lyophilized uropathogenic bacteria is placed in a flask. A portion of the liquid suppository base is cooled to 60°C and poured into individual flasks containing the vaccine. The vaccine and the liquid suppository base are stirred for about 10 minutes at a temperature of about 60°C forming a homogeneous suspension comprised of the suppository base and the
15 vaccine. The suspension comprised of the suppository base and the vaccine is placed into individual laminate suppository shells. An additional amount of liquid suppository base is added to the flask which contains residue of vaccine. The suppository base and the vaccine are stirred for about 1 minute at a temperature of 60°C to form a homogeneous suspension. This suspension is added to the laminate suppository shell. Pure liquid
20 suppository base is added to the top of the laminate suppository shell until the shell is filled. The suppository is cooled at a temperature of about 24°C allowing the suppository base to harden. This method ensures that the active vaccine materials are located in the

bottom 67% of the suppository where it is protected from the cracking or flaking that may occur in the tip of the suppository when shells are opened for use.

The present invention is further exemplified in the following example. The example illustrates the effectiveness of the suppository-based vaccine delivery system of the present invention. It is understood that the example is only illustrative of preferred
5 embodiments according to the present invention wherein the claims set forth the scope of the present invention.

EXAMPLE

10 A suppository-based vaccine delivery system comprised of a vaccine comprised of inactivated bacteria which originate from cultures of 8 to 14 uropathogenic bacteria strains isolated from the urine of persons suffering from a urinary tract infection of the species: *Escherichia coli*, *Klebsiella pneumoniae*, *Proteus mirabilis*, *Proteus
15 morgani*, and *Streptococcus faecalis*, and are present in an amount of about 50 million to about 5 billion germs of each strain per suppository, wherein one-half to three-quarters of the strains used belong to *Escherichia coli* species; and polyethylene glycol suppository base; was prepared.

POLYBASE, a polyethylene glycol suppository base manufactured by Paddock Laboratories, Inc., was heated to a temperature of 80°C for about one hour to
20 liquefy the suppository base. Lyophilized SOLCOUROVAC® vaccine manufactured by Solco Basel AG, was aseptically placed in a sterile Erlenmeyer flask, enough to manufacture 50 suppositories. Each suppository will contain from about 1×10^9 to about

1x10¹⁰ germs. The liquid suppository base was cooled to about 60°C and approximately 100 ml of liquid suppository base was poured into the individual flasks containing the vaccine. A sterile magnetic stir bar was placed in the flask, and the vaccine and suppository base were stirred for about 10 minutes at approximately 60°C in a temperature controlled water bath to form a homogeneous suspension. The suspension comprised of the suppository base and the vaccine was placed into individual polyvinyl chloride-polyethylene laminate suppository shell using a sterile pipette. Approximately 2.0 ml of the suspension was placed into each shell.

Approximately 25ml of liquid suppository base is added to the flask which contained residue of the vaccine. The suppository base and the vaccine were stirred for about 1 minute at a temperature of about 60°C to form a homogeneous suspension. Approximately 0.5ml of this suspension was added to each shell. Pure liquid suppository base was added to each shell to fill the shell. The suppository base was cooled at a temperature of about 24°C for about 30 minutes to harden the suppository base. The suppositories were then stored at 4°C.

Ninety one women patients, aged 18 to 82, participated in the testing of the suppository. The patients all had more than two urinary tract infections during the last year and all had an evaluation consisting of excretory urography or renal ultrasound and cystoscopy. Complete blood count, blood chemistry studies, urinalysis and culture, and speculum vaginal examination were performed on the patients prior to testing the suppository. The patients were counseled against becoming pregnant during the testing and had to have negative urine pregnancy test prior to testing.

The 91

patients were divided into three treatment groups. Group 1 received suppositories containing about 1×10^9 germs per suppository. Group 2 received suppositories containing about 2×10^9 germs per suppository. Group 3 received suppositories which did not contain the vaccine. The three groups of patients did not differ in mean age, hysterectomy status, sexual activity, or being on antibiotic prophylaxis during weeks 0-4.

The suppositories were administered three times at weekly intervals to each patient. The suppositories were administered vaginally. For vaginal suppository placement, the patients were placed in a supine position and the suppository was placed in the high vagina. The patients remained in the supine position for approximately 15 minutes. All patients were seen 4 weeks after the first treatment, and then at 4 week intervals through week 20. Serum, urine, and vaginal irrigates were collected at each visit. Vaginal cultures were done when abnormal vaginal secretions or symptoms developed during the testing.

Of the 91 patients, 44 who were on antibiotic prophylaxis at the outset of the testing continued taking antibiotics until 2 weeks after the third suppository installation. The remaining 47 were off prophylaxis regimens throughout the testing.

Patient characteristics were statistically compared with Fisher's two-tailed exact test and Kruskal-Wallis one way ANOVA. Times until first reinfection were compared with the log rank test. Such tests are fully explained in SAS/STAT Software, Changes and Enhancements, Ed. 6.07, Cary, SAS Institute, Inc., p. 620, 1993. Most infections were documented by urine culture and sensitivity, and treated for 3 days with

full doses of conventional antibiotics. Episodes of typical bladder irritative symptoms which responded promptly to antibiotics available at home, but not verified by urine culture, were also counted as recurring infections and analyzed in the same manner. Changes in antibody levels during the course were compared by repeated measures ANOVA for unbalanced data.

No patients discontinued treatment for adverse reactions. One patient complained of a light-headed episode after returning home from the first vaccine, but received the second and third vaccination uneventfully and on schedule. Three other patients reported minor vaginal irritation following suppository insertions but were able to complete the three-suppository regimen without interruption. There were no other reports of episodes of heavy vaginal discharge, interference with sexual intercourse, or signs and symptoms of bacterial vaginosis.

Initial analysis of all 91 patients did not show different clinical courses between placebo and treated groups. This lack of treatment effect was due to the fact that both placebo- and vaccine-treated patients on antibiotic prophylaxis for the first 4 weeks of the study were experiencing fewer urinary tract infections. When examining the reinfection times of the 47 women off prophylaxis from week 0, the treated group experienced a significant initial delay in the time until first reinfection. There was no significant difference in the time until first infection for the low-dose and high dose groups, so these data were combined in the analysis for vaccine efficacy. The results showed that the number of patients not experiencing infection through 8 weeks was significantly greater in vaccine-treated than placebo-treated groups. In addition, the mean

time until first infection was delayed from 8.7 weeks to 13 weeks in immunized patients. Fig. 1 is a graph illustrating the percentage of patients remaining infection free during the testing. Those patients in Group 1 are represented by the dotted line. The patients in Groups 2 and 3 are represented by the solid line.

5 The suppository-based vaccine delivery system according to the present invention allows the vaccine to be in contact with the vaginal mucous membrane for a sufficient period of time to enhance the immune response. Further, the suppository-based vaccine delivery system according to the present invention is easily administered, does not require the patient to lie in a supine position for an extended period of time after
10 receiving the vaccination, is suitably administered by the patient, is painless, is amenable to routine urinary tract infections booster vaccination, and allows a favorable method of antigen delivery to immunocompetent cells through the mucosa.

 While various embodiments of a suppository-based vaccine delivery system for treating urinary tract infections and a method for treating urinary tract
15 infections in humans have been disclosed, it should be understood that modifications and adaptations thereof will occur to persons skilled in the art. Other features and aspects of this invention will be appreciated by those skilled in the art upon reading and comprehending this disclosure. Such features, aspects, and expected variations and modifications of the reported results and examples are clearly within the scope of the
20 invention where the invention is limited solely by the scope of the following claims.

Having thus described the invention, it is now claimed:

1. A suppository-based vaccine delivery system for prophylaxis against urogenital disease in humans, said suppository comprising:

(a) a vaccine comprised of inactivated bacteria which originate from cultures of 8 to 14 uropathogenic bacteria strains of the species: *Escherichia coli*,
5 *Klebsiella pneumoniae*, *Proteus mirabilis*, *Proteus morganii*, and *Streptococcus faecalis*, and are present in an amount of about 50 million to about 5 billion germs of each strain per milliliter, wherein one-half to three-quarters of the strains used belong to *Escherichia coli* species; and

(b) polyethylene glycol suppository base,

10 wherein the suppository is adapted to be inserted into a bodily orifice of a human so as to allow the suppository to be in contact with tissue of the bodily orifice to facilitate transfer of suppository material therethrough.

2. A suppository-based vaccine delivery system for prophylaxis against urinary tract infections in humans, said suppository comprising:

(a) a vaccine comprised of inactivated bacteria which originate from cultures of 8 to 14 uropathogenic bacteria strains isolated from the urine of persons
5 suffering from a urinary tract infection of the species: *Escherichia coli*, *Klebsiella pneumoniae*, *Proteus mirabilis*, *Proteus morganii*, and *Streptococcus faecalis*, and are present in an amount of about 50 million to about 5 billion germs of each strain per

suppository, wherein one-half to three-quarters of the strains used belong to *Escherichia coli* species; and

- 10 (b) polyethylene glycol suppository base,
 wherein the suppository is adapted to be inserted vaginally so as to allow the suppository to be in contact with vaginal mucous membrane to facilitate transfer of suppository material therethrough.

3. The suppository-based vaccine delivery system of claim 2 wherein the inactive bacteria originate from 6 strains of the species *Escherichia coli* and 1 strain each of *Klebsiella pneumoniae*, *Proteus mirabilis*, *Proteus morganii*, and *Streptococcus faecalis*.

4. The suppository-based vaccine delivery system of claim 2 wherein the inactive bacteria are present in the total amount of about 1×10^9 to about 1×10^{10} germs.

5. The suppository-based vaccine delivery system of claim 2 wherein the polyethylene glycol suppository base is comprised of polyethylene glycol and polysorbate.

6. The suppository-based vaccine delivery system of claim 5 wherein the polyethylene glycol suppository base is comprised of about 98% by weight polyethylene glycol and about 2% by weight polysorbate.

7. The suppository-based vaccine delivery system of claim 5 wherein the polyethylene glycol has an average molecular weight of about 3000 to about 5000.

8. The suppository-based vaccine delivery system of claim 2 wherein the polyethylene glycol suppository base comprises from about 80% to about 95% by weight of the suppository.

9. The suppository-based vaccine delivery system of claim 2 wherein the suppository is further comprised of depolarized gelatin.

10. The suppository-based vaccine delivery system of claim 9 wherein the depolarized gelatin is selected from the group consisting of type A gelatin from bovine collagen, type A gelatin from porcine collagen, type B gelatin from bovine collagen, and type B gelatin from porcine collagen.

11. The suppository-based vaccine delivery system of claim 9 wherein the suppository is comprised of about 0.01% to about 0.02% by weight of depolarized gelatin.

12. The suppository-based vaccine delivery system of claim 2 wherein the suppository is further comprised of thimerosal.

13. The suppository-based vaccine delivery system of claim 12 wherein the suppository is comprised of about 0.0005% to about 0.005% by weight of thimerosal.

14. A suppository-based vaccine delivery system for prophylaxis against urinary tract infections in humans, said suppository comprising:

(a) a vaccine comprised of inactivated bacteria which originate from cultures of 8 to 14 uropathogenic bacteria strains isolated from the urine of persons suffering from a urinary tract infection of the species: *Escherichia coli*, *Klebsiella pneumoniae*, *Proteus mirabilis*, *Proteus morganii*, and *Streptococcus faecalis*, and are present in an amount of about 50 million to about 5 billion germs of each strain per suppository, wherein one-half to three-quarters of the strains used belong to *Escherichia coli* species, wherein the inactive bacteria originate from 6 strains of the species *Escherichia coli* and 1 strain each of *Klebsiella pneumoniae*, *Proteus mirabilis*, *Proteus morganii*, and *Streptococcus faecalis*, and wherein the inactive bacteria are present in the total amount of about 1×10^9 to about 1×10^{10} germs; and

(b) polyethylene glycol suppository base,

wherein the polyethylene glycol suppository base is comprised of about 98% by weight polyethylene glycol and about 2% by weight polysorbate, wherein the polyethylene glycol has an average molecular weight of about 3000 to about 5000, and wherein the polyethylene glycol suppository base comprises from about 80% to about 95% by weight of the suppository; wherein the suppository is adapted to be inserted

20 vaginally so as to allow the suppository to be in contact with vaginal mucous membrane
to facilitate transfer of suppository material therethrough.

5 15. The suppository-based vaccine delivery system of claim 14 wherein the
suppository is further comprised of depolarized gelatin and thimerosal, wherein the
depolarized gelatin is selected from the group consisting of type A gelatin from bovine
collagen, type A gelatin from porcine collagen, type B gelatin from bovine collagen, and
type B gelatin from porcine collagen, wherein the suppository is comprised of about
0.01% to about 0.02% by weight of depolarized gelatin, and wherein the suppository is
comprised of about 0.0005% to about 0.005% by weight of thimerosal.

16. A suppository-based vaccine delivery system for prophylaxis against
urinary tract infections in humans, said suppository resulting from the mixture of:

5 (a) a vaccine comprised of inactivated bacteria which originate from
cultures of 8 to 14 uropathogenic bacteria strains isolated from the urine of persons
suffering from a urinary tract infection of the species: *Escherichia coli*, *Klebsiella*
pneumoniae, *Proteus mirabilis*, *Proteus morganii*, and *Streptococcus faecalis*, and are
present in an amount of about 50 million to about 5 billion germs of each strain per
suppository, wherein one-half to three-quarters of the strains used belong to *Escherichia*
coli species, wherein the inactive bacteria originate from 6 strains of the species
10 *Escherichia coli* and 1 strain each of *Klebsiella pneumoniae*, *Proteus mirabilis*, *Proteus*

morganii, and *Streptococcus faecalis*, and wherein the inactive bacteria are present in the total amount of about 1×10^9 to about 1×10^{10} germs; and

(b) polyethylene glycol suppository base,

wherein the polyethylene glycol suppository base is comprised of about
15 98% by weight polyethylene glycol and about 2% by weight polysorbate, wherein the polyethylene glycol has an average molecular weight of about 3000 to about 5000, and wherein the polyethylene glycol suppository base comprises from about 80% to about 90% by weight of the suppository; wherein the suppository is adapted to be inserted vaginally so as to allow the suppository to be in contact with vaginal mucous membrane
20 to facilitate transfer of suppository material therethrough.

17. A method for preventing urogenital disease in humans, said method comprising the steps of:

(a) inserting a suppository-based vaccine delivery system into a bodily
orifice of a human, wherein said suppository is comprised of a vaccine comprised of
5 inactivated bacteria which originate from cultures of 8 to 14 uropathogenic bacteria strains of the species: *Escherichia coli*, *Klebsiella pneumoniae*, *Proteus mirabilis*, *Proteus morganii*, and *Streptococcus faecalis*, and are present in an amount of about 50 million to about 5 billion germs of each strain per suppository, wherein one-half to three-quarters of the strains used belong to *Escherichia coli* species; and polyethylene glycol
10 suppository base; and

(b) contacting the suppository with tissue of the bodily orifice to facilitate transfer of suppository material therethrough and induce an immune response in the human.

18. A method of preventing urinary tract infections in humans, said method comprising the steps of:

(a) inserting a suppository-based vaccine delivery system into a vagina of a human, wherein said suppository is comprised of a vaccine comprised of inactivated bacteria which originate from cultures of 8 to 14 uropathogenic bacteria strains of the species: *Escherichia coli*, *Klebsiella pneumoniae*, *Proteus mirabilis*, *Proteus morganii*, and *Streptococcus faecalis*, and are present in an amount of about 50 million to about 5 billion germs of each strain per suppository, wherein one-half to three-quarters of the strains used belong to *Escherichia coli* species; and polyethylene glycol suppository base; and

(b) contacting the suppository with vaginal mucous membrane to facilitate transfer of suppository material therethrough and induce an immune response in the human.

19. The method of claim 18 wherein the inactive bacteria originate from 6 strains of the species *Escherichia coli* and 1 strain each of *Klebsiella pneumoniae*, *Proteus mirabilis*, *Proteus morganii*, and *Streptococcus faecalis*.

20. The method of claim 18 wherein the inactive bacteria are present in the total amount of about 1×10^9 to about 1×10^{10} germs.
21. The method of claim 18 wherein the polyethylene glycol suppository base is comprised of polyethylene glycol and polysorbate.
22. The method of claim 21 wherein the polyethylene glycol suppository base is comprised of about 98% by weight polyethylene glycol and about 2% by weight polysorbate.
23. The method of claim 21 wherein the polyethylene glycol has an average molecular weight of about 3000 to about 5000.
24. The method of claim 18 wherein the polyethylene glycol suppository base comprises from about 80% to about 95% by weight of the suppository.
25. The method of claim 18 wherein the suppository is further comprised of depolarized gelatin.
26. The method of claim 25 wherein the depolarized gelatin is selected from the group consisting of type A gelatin from bovine collagen, type A gelatin from porcine collagen, type B gelatin from bovine collagen, and type B gelatin from porcine collagen.

27. The method of claim 25 wherein the suppository is comprised of about 0.01% to about 0.02% by weight of depolarized gelatin.

28. The method of claim 18 wherein the suppository is further comprised of thimerosal.

29. The method of claim 28 wherein the suppository is comprised of about 0.0005% to about 0.005% by weight of thimerosal.




Fig. 1

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/18402

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 6 A61K39/116 A61K9/02

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	D.T. UEHLING ET AL.: "VAGINAL MUCOSAL IMMUNIZATION FOR RECURRENT URINARY TRACT INFECTION: PHASE II CLINICAL TRIAL." THE JOURNAL OF UROLOGY, vol. 157, no. 6, June 1997, pages 2049-2052, XP002089704 BALTIMORE, PA, US see the whole document -----	1-29
A	EP 0 173 241 A (SOLCO BASEL AG) 5 March 1986 see claims & US 4 606 919 A cited in the application -----	1-29

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

12 January 1999

Date of mailing of the international search report

22/01/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Ryckebosch, A

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 98/18402

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 17-29 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
- No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 98/18402

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 173241 A	05-03-1986	CH 664497 A	15-03-1988
		CA 1252722 A	18-04-1989
		DK 397085 A	01-03-1986
		JP 61060618 A	28-03-1986
		PT 81063 B	22-01-1988
		SU 1452462 A	15-01-1989
		US 4606919 A	19-08-1986
